• AstraZeneca to Delist from Nasdaq, Complete Direct Listing on NYSE
CAMBRIDGE, UK – AstraZeneca announced on Tuesday it will voluntarily delist its American Depositary Shares and debt securities from the Nasdaq stock market, with plans to complete a direct listing on the New York Stock Exchange.
The company expects trading on the NYSE to commence on February 2, 2026.
What is new?
AstraZeneca PLC provided notice on January 20, 2026, of its voluntary withdrawal from The Nasdaq Stock Market LLC.
The withdrawal applies to its American Depositary Shares (ADSs), which represent the company’s ordinary shares, as well as certain debt securities issued by the company or its subsidiary, AstraZeneca Finance LLC. The move precedes a planned direct listing of its Ordinary Shares and the Debt Securities on the New York Stock Exchange (NYSE).
Key Details and Timeline
The company’s listing of ADSs and Debt Securities on Nasdaq is expected to cease after the market closes on January 30, 2026. Trading of the Ordinary Shares and Debt Securities is scheduled to begin on the NYSE from Monday, February 2, 2026. AstraZeneca confirmed that its ticker symbol for ordinary shares will remain “AZN”.
Strategic Rationale
This action is part of a shareholder-approved plan, first announced on September 29, 2025, to harmonize the company’s share listing structure. The objective is to create a single global listing to serve investors worldwide. Following the implementation, shareholders will be able to trade their interests in the company’s Ordinary Shares across the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange.
About this company
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. The company focuses on the discovery, development, and commercialization of prescription medicines in the fields of Oncology, Rare Diseases, and BioPharmaceuticals, which includes Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s medicines are sold in more than 125 countries and are used by millions of patients globally.
Related Topics
Stellantis Medium Platform Allows EVs To Travel ~1000 Km On Just 2 Charges
Update: Fresenius Welcomes Over 2,750 New Trainees and Dual Students in 2024